BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 20522446)

  • 1. Good clinical response to gefitinib in a non-small cell lung cancer patient harboring a rare somatic epidermal growth factor gene point mutation; codon 768 AGC > ATC in exon 20 (S768I).
    Masago K; Fujita S; Irisa K; Kim YH; Ichikawa M; Mio T; Mishima M
    Jpn J Clin Oncol; 2010 Nov; 40(11):1105-9. PubMed ID: 20522446
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib.
    Riely GJ; Pao W; Pham D; Li AR; Rizvi N; Venkatraman ES; Zakowski MF; Kris MG; Ladanyi M; Miller VA
    Clin Cancer Res; 2006 Feb; 12(3 Pt 1):839-44. PubMed ID: 16467097
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of clinical outcome of patients with non-small-cell lung cancer harbouring epidermal growth factor receptor exon 19 or exon 21 mutations.
    Won YW; Han JY; Lee GK; Park SY; Lim KY; Yoon KA; Yun T; Kim HT; Lee JS
    J Clin Pathol; 2011 Nov; 64(11):947-52. PubMed ID: 21725039
    [TBL] [Abstract][Full Text] [Related]  

  • 4. First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations.
    Sequist LV; Martins RG; Spigel D; Grunberg SM; Spira A; Jänne PA; Joshi VA; McCollum D; Evans TL; Muzikansky A; Kuhlmann GL; Han M; Goldberg JS; Settleman J; Iafrate AJ; Engelman JA; Haber DA; Johnson BE; Lynch TJ
    J Clin Oncol; 2008 May; 26(15):2442-9. PubMed ID: 18458038
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Double mutation and gene copy number of EGFR in gefitinib refractory non-small-cell lung cancer.
    Tokumo M; Toyooka S; Ichihara S; Ohashi K; Tsukuda K; Ichimura K; Tabata M; Kiura K; Aoe M; Sano Y; Date H; Shimizu N
    Lung Cancer; 2006 Jul; 53(1):117-21. PubMed ID: 16730855
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gefitinib-sensitive mutations of the epidermal growth factor receptor tyrosine kinase domain in chinese patients with non-small cell lung cancer.
    Mu XL; Li LY; Zhang XT; Wang MZ; Feng RE; Cui QC; Zhou HS; Guo BQ
    Clin Cancer Res; 2005 Jun; 11(12):4289-94. PubMed ID: 15958609
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EGFR mutants found in non-small cell lung cancer show different levels of sensitivity to suppression of Src: implications in targeting therapy.
    Fu YN; Yeh CL; Cheng HH; Yang CH; Tsai SF; Huang SF; Chen YR
    Oncogene; 2008 Feb; 27(7):957-65. PubMed ID: 17653080
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib.
    Kosaka T; Yatabe Y; Endoh H; Yoshida K; Hida T; Tsuboi M; Tada H; Kuwano H; Mitsudomi T
    Clin Cancer Res; 2006 Oct; 12(19):5764-9. PubMed ID: 17020982
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors for brain metastasis in non-small cell lung cancer patients harboring either exon 19 or 21 mutation.
    Park SJ; Kim HT; Lee DH; Kim KP; Kim SW; Suh C; Lee JS
    Lung Cancer; 2012 Sep; 77(3):556-60. PubMed ID: 22677429
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib.
    Han SW; Kim TY; Hwang PG; Jeong S; Kim J; Choi IS; Oh DY; Kim JH; Kim DW; Chung DH; Im SA; Kim YT; Lee JS; Heo DS; Bang YJ; Kim NK
    J Clin Oncol; 2005 Apr; 23(11):2493-501. PubMed ID: 15710947
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Denaturing capillary electrophoresis for automated detection of L858R mutation in exon 21 of the epidermal growth factor receptor gene in prediction of the outcome of lung cancer therapy.
    Benesova L; Pesek M; Belsanova B; Sekerka P; Minarik M
    J Sep Sci; 2010 Aug; 33(15):2349-55. PubMed ID: 20574956
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The close correlation between 8-hydroxy-2'-deoxyguanosine and epidermal growth factor receptor activating mutation in non-small cell lung cancer.
    Kawahara A; Azuma K; Hattori S; Nakashima K; Basaki Y; Akiba J; Takamori S; Aizawa H; Yanagawa T; Izumi H; Kohno K; Kono S; Kage M; Kuwano M; Ono M
    Hum Pathol; 2010 Jul; 41(7):951-9. PubMed ID: 20236686
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence.
    Mitsudomi T; Kosaka T; Endoh H; Horio Y; Hida T; Mori S; Hatooka S; Shinoda M; Takahashi T; Yatabe Y
    J Clin Oncol; 2005 Apr; 23(11):2513-20. PubMed ID: 15738541
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activity of epidermal growth factor receptor-tyrosine kinase inhibitors in patients with non-small cell lung cancer harboring rare epidermal growth factor receptor mutations.
    De Pas T; Toffalorio F; Manzotti M; Fumagalli C; Spitaleri G; Catania C; Delmonte A; Giovannini M; Spaggiari L; de Braud F; Barberis M
    J Thorac Oncol; 2011 Nov; 6(11):1895-901. PubMed ID: 21841502
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan.
    Huang SF; Liu HP; Li LH; Ku YC; Fu YN; Tsai HY; Chen YT; Lin YF; Chang WC; Kuo HP; Wu YC; Chen YR; Tsai SF
    Clin Cancer Res; 2004 Dec; 10(24):8195-203. PubMed ID: 15623594
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acquired resistance to gefitinib: the contribution of mechanisms other than the T790M, MET, and HGF status.
    Onitsuka T; Uramoto H; Nose N; Takenoyama M; Hanagiri T; Sugio K; Yasumoto K
    Lung Cancer; 2010 May; 68(2):198-203. PubMed ID: 19589612
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intron 1 CA dinucleotide repeat polymorphism and mutations of epidermal growth factor receptor and gefitinib responsiveness in non-small-cell lung cancer.
    Han SW; Jeon YK; Lee KH; Keam B; Hwang PG; Oh DY; Lee SH; Kim DW; Im SA; Chung DH; Heo DS; Bang YJ; Kim TY
    Pharmacogenet Genomics; 2007 May; 17(5):313-9. PubMed ID: 17429313
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the efficacy of gefitinib in patients with non-small cell lung cancer according to the type of epidermal growth factor receptor mutation.
    Igawa S; Kasajima M; Ishihara M; Kimura M; Hiyoshi Y; Asakuma M; Otani S; Katono K; Sasaki J; Masuda N
    Oncology; 2014; 87(4):215-23. PubMed ID: 25034225
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lung cancer with epidermal growth factor receptor exon 20 mutations is associated with poor gefitinib treatment response.
    Wu JY; Wu SG; Yang CH; Gow CH; Chang YL; Yu CJ; Shih JY; Yang PC
    Clin Cancer Res; 2008 Aug; 14(15):4877-82. PubMed ID: 18676761
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Complex mutations in the epidermal growth factor receptor gene in non-small cell lung cancer.
    Hata A; Yoshioka H; Fujita S; Kunimasa K; Kaji R; Imai Y; Tomii K; Iwasaku M; Nishiyama A; Ishida T; Katakami N
    J Thorac Oncol; 2010 Oct; 5(10):1524-8. PubMed ID: 20808254
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.